» Articles » PMID: 33990769

MTOR Kinase Activity Disrupts a Phosphorylation Signaling Network in Schizophrenia Brain

Overview
Journal Mol Psychiatry
Date 2021 May 15
PMID 33990769
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The AKT-mTOR signaling transduction pathway plays an important role in neurodevelopment and synaptic plasticity. mTOR is a serine/threonine kinase that modulates signals from multiple neurotransmitters and phosphorylates specific proteins to regulate protein synthesis and cytoskeletal organization. There is substantial evidence demonstrating abnormalities in AKT expression and activity in different schizophrenia (SZ) models. However, direct evidence for dysregulated mTOR kinase activity and its consequences on downstream effector proteins in SZ pathophysiology is lacking. Recently, we reported reduced phosphorylation of mTOR at an activating site and abnormal mTOR complex formation in the SZ dorsolateral prefrontal cortex (DLPFC). Here, we expand on our hypothesis of disrupted mTOR signaling in the SZ brain and studied the expression and activity of downstream effector proteins of mTOR complexes and the kinase activity profiles of SZ subjects. We found that S6RP phosphorylation, downstream of mTOR complex I, is reduced, whereas PKCα phosphorylation, downstream of mTOR complex II, is increased in SZ DLPFC. In rats chronically treated with haloperidol, we showed that S6RP phosphorylation is increased in the rat frontal cortex, suggesting a potential novel mechanism of action for antipsychotics. We also demonstrated key differences in kinase signaling networks between SZ and comparison subjects for both males and females using kinome peptide arrays. We further investigated the role of mTOR kinase activity by inhibiting it with rapamycin in postmortem tissue and compared the impact of mTOR inhibition in SZ and comparison subjects using kinome arrays. We found that SZ subjects are globally more sensitive to rapamycin treatment and AMP-activated protein kinase (AMPK) contributes to this differential kinase activity. Together, our findings provide new insights into the role of mTOR as a master regulator of kinase activity in SZ and suggest potential targets for therapeutic intervention.

Citing Articles

βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia.

Di Re J, Marini M, Hussain S, Singh A, Venkatesh A, Alshammari M Mol Psychiatry. 2025; .

PMID: 39920295 DOI: 10.1038/s41380-025-02917-1.


Psychedelics and schizophrenia: a double-edged sword.

Sapienza J, Martini F, Comai S, Cavallaro R, Spangaro M, De Gregorio D Mol Psychiatry. 2024; 30(2):679-692.

PMID: 39294303 DOI: 10.1038/s41380-024-02743-x.


Analysis of single-cell transcriptome data from a mouse model implicates protein synthesis dysfunction in schizophrenia.

Weller A, Ferraro T, Doyle G, Reiner B, Berrettini W, Crist R Genes Genomics. 2024; 46(9):1071-1084.

PMID: 39083157 DOI: 10.1007/s13258-024-01545-3.


Decoding frontotemporal and cell-type-specific vulnerabilities to neuropsychiatric disorders and psychoactive drugs.

Ji J, Chao H, Chen H, Liao J, Shi W, Ye Y Open Biol. 2024; 14(6):240063.

PMID: 38864245 PMC: 11285532. DOI: 10.1098/rsob.240063.


Modulation of mGlu5 reduces rewarding associative properties of nicotine via changes in mesolimbic plasticity: Relevance to comorbid cigarette smoking in psychosis.

Peeters L, Wills L, Cuozzo A, Ivanich K, Turney S, Bullock L Pharmacol Biochem Behav. 2024; 239():173752.

PMID: 38521210 PMC: 11088493. DOI: 10.1016/j.pbb.2024.173752.


References
1.
Owen M, Sawa A, Mortensen P . Schizophrenia. Lancet. 2016; 388(10039):86-97. PMC: 4940219. DOI: 10.1016/S0140-6736(15)01121-6. View

2.
Funk A, McCullumsmith R, Haroutunian V, Meador-Woodruff J . Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology. 2011; 37(4):896-905. PMC: 3280643. DOI: 10.1038/npp.2011.267. View

3.
Kyosseva S, Elbein A, Griffin W, Mrak R, Lyon M, Karson C . Mitogen-activated protein kinases in schizophrenia. Biol Psychiatry. 1999; 46(5):689-96. DOI: 10.1016/s0006-3223(99)00104-3. View

4.
Emamian E . AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. 2012; 5:33. PMC: 3304298. DOI: 10.3389/fnmol.2012.00033. View

5.
Emamian E, Hall D, Birnbaum M, Karayiorgou M, Gogos J . Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004; 36(2):131-7. DOI: 10.1038/ng1296. View